1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1097/mjt.0b013e3181bdc3d0" target="_blank" rel="noreferrer noopener">http://doi.org/10.1097/mjt.0b013e3181bdc3d0</a>
Pages
313–322
Issue
4
Volume
18
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Cinacalcet for the treatment of primary hyperparathyroidism.
Publisher
An entity responsible for making the resource available
American Journal of Therapeutics
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-07
Subject
The topic of the resource
Female; Hormone Replacement Therapy; Hydrocarbons – Therapeutic Use; Bone Density – Drug Effects; Calcitonin – Therapeutic Use; Diphosphonates – Therapeutic Use; Estrogens – Therapeutic Use; Hormone Antagonists – Pharmacodynamics; Hormone Antagonists – Therapeutic Use; Hydrocarbons – Pharmacodynamics; Hyperparathyroidism – Complications; Hyperparathyroidism – Drug Therapy; Osteoporosis – Drug Therapy; Osteoporosis – Etiology; Raloxifene – Therapeutic Use
Creator
An entity primarily responsible for making the resource
Dillon ML; Frazee L A
Description
An account of the resource
The objective of this article is to review the literature regarding the treatment of primary hyperparathyroidism (PHPT) with a focus on cinacalcet. A MEDLINE (1965-June 2009) and bibliographic search of the English-language literature was conducted using the search terms cinacalcet, calcimimetics, primary hyperparathyroidism, and treatment. All articles identified in the search were included. Parathyroidectomy is curative for patients with PHPT; however, there are few options for patients who are not surgical candidates, who refuse surgery, or those with refractory PHPT after parathyroidectomy. Possible treatment options include estrogens, raloxifene, bisphosphonates, calcitonin, and cinacalcet. Cinacalcet has been shown to decrease serum calcium and parathyroid hormone serum levels in patients with PHPT. These trials, however, have not studied the effect of cinacalcet on patient-oriented outcomes such as bone mineral density, nephrolithiasis, or other complications of PHPT. Cinacalcet may be considered to reduce serum calcium and parathyroid hormone serum levels in patients with PHPT who cannot or will not undergo surgery and those with refractory PHPT after parathyroidectomy. Because the effects of cinacalcet on bone mineral density are uncertain, more frequent monitoring of bone mineral density may be required along with a medication proven to improve bone mineral density. Future studies should evaluate the effect of cinacalcet on complications of PHPT.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1097/mjt.0b013e3181bdc3d0" target="_blank" rel="noreferrer noopener">10.1097/mjt.0b013e3181bdc3d0</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2011
American journal of therapeutics
Bone Density – Drug Effects
Calcitonin – Therapeutic Use
Department of Internal Medicine
Dillon ML
Diphosphonates – Therapeutic Use
Estrogens – Therapeutic Use
Female
Frazee L A
Hormone Antagonists – Pharmacodynamics
Hormone Antagonists – Therapeutic Use
Hormone Replacement Therapy
Hydrocarbons – Pharmacodynamics
Hydrocarbons – Therapeutic Use
Hyperparathyroidism – Complications
Hyperparathyroidism – Drug Therapy
NEOMED College of Medicine
Osteoporosis – Drug Therapy
Osteoporosis – Etiology
Raloxifene – Therapeutic Use